Tibes, Raoul <br/><br/>
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?  [electronic resource] 

 -  Leukemia & lymphoma  Jul 2011 
 - 1178-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2011.566952  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Humans<br/>Janus Kinase 2--antagonists & inhibitors<br/>Leukemia--drug therapy<br/>Mutation--genetics<br/>Myeloproliferative Disorders--drug therapy<br/>Neoplasm Staging<br/>Primary Myelofibrosis--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use